MTITSE:9438 -0.37%72 EBITDA Margin % is 23.39% as of Mar. 2026, which is 49% above its 10-year median of 15.65. GuruFocus rates TSE:9438 with a GF Score™ of 72/100 and a GF Value™ of 円847.15 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 665 Healthcare Providers & Services companies, MTI ranks better than 69.47% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. MTI's EBITDA for the
three
months ended in Mar. 2026 was 円1,847 Mil. MTI's Revenue for the
three
months ended in Mar. 2026 was 円7,893 Mil. Therefore, MTI's EBITDA margin for the quarter that ended in Mar. 2026 was 23.39%.
MTI (TSE:9438) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
MTI EBITDA Margin % Related Terms
MTI EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for MTI's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:9438 vs VEEV, BTSG, TEM: EBITDA Margin % Comparison
For the Health Information Services subindustry, MTI's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MTI EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MTI's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where MTI's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MTI (TSE:9438) has a EBITDA Margin % of 23.39% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MTI and its competitors. This is 49% above median its historical median of 15.65. Over the past decade, MTI's EBITDA Margin % has ranged from 5.44 to 20.14. According to the industry distribution chart, MTI ranks #203 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 30.5%.
Is MTI's EBITDA Margin % too high?
MTI's current EBITDA Margin % of 23.39% is 49% above median its 10-year median of 15.65. Over the past 10 years, this metric has ranged from a low of 5.44 to a high of 20.14. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. MTI's value of 23.39% is 128.4% above this industry median. Based on the distribution chart, MTI ranks #203 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MTI has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MTI's EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MTI ranks #203 out of 665 companies for EBITDA Margin %. This puts MTI in the upper half of its industry. The industry median EBITDA Margin % is 10.24. MTI's value of 23.39% is 128.4% above this benchmark. Historically, MTI's own EBITDA Margin % has ranged from 5.44 to 20.14 over the past decade. While the company's 10-year median is 15.65 vs. the industry median of 10.24, MTI has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MTI's current EBITDA Margin % of 23.39% is 128.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on MTI and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MTI's current EBITDA Margin % is 23.39%, which is 49% above median its own 10-year median of 15.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MTI stock overvalued right now?
Based on GuruFocus' analysis, MTI (TSE:9438) is currently considered Significantly Undervalued. The stock's GF Value™ is 円847.15, compared to a current price of 円536.00 — trading 36.7% below its estimated fair value. The current EBITDA Margin % is 23.39%, which is 49% above median its 10-year median of 15.65 and 128.4% above the Healthcare Providers & Services industry median of 10.24. MTI's overall GF Score™ is 72/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For MTI (TSE:9438), the current EBITDA Margin % is 23.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MTI (TSE:9438) Overvalued in 2026?
Based on GuruFocus' analysis, MTI stock appears to be undervalued.
The current stock price of 円536.00 is trading 36.7% below its estimated GF Value™ of 円847.15.
GuruFocus considers MTI to be Significantly Undervalued.
Key valuation signals for TSE:9438:
EBITDA Margin %: 23.39% (49% above median its 10-year median of 15.65)
GF Value™: 円847.15 vs. price of 円536.00 (36.7% below fair value)
Industry Position: 128.4% above the Healthcare Providers & Services median (#203 of 665)
No single metric tells the full story. See the TSE:9438 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MTI Ltd is engaged in the content distribution business for mobile phones in Japan. The company provides health care services through Lunaruna app, Lunaruna baby, and Lunaruna medicine notebook. It is involved in providing music/video services, electronic book services, life information services, and entertainment services.
72GF Score
Get the complete analysis for TSE:9438
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9438 has been successfully added to your 
